0001628280-26-017242
SEC filingAllogene Therapeutics, Inc. reported a net loss of $190.9 million for the fiscal year ended December 31, 2025, compared to a net loss of $257.6 million in the prior year, representing a 26% improvement. The company generated no collaboration revenue in FY 2025, down from $22,000 in FY 2024. Total operating expenses decreased by 23% to $209.3 million, driven by reductions in research and development (down 22% to $150.2 million) and general and administrative expenses (down 13% to $56.8 million). The company ended the period with $93.4 million in cash, cash equivalents, and restricted cash, a decrease of $23.5 million from the prior year-end. Key forward-looking items include anticipated clinical readouts in 2026 for its core programs (ALPHA3, RESOLUTION, TRAVERSE) and an expected cash runway into the first quarter of 2028.
Allogene Therapeutics, Inc. reported a net loss of $190.9 million for the fiscal year ended December 31, 2025, an improvement from a net loss of $257.6 million in the prior year. The company recorded no collaboration revenue in FY 2025, compared to $22,000 in FY 2024. Total operating expenses decreased by 23% to $209.3 million, primarily due to a $42.1 million reduction in research and development expenses (to $150.2 million) and an $8.4 million reduction in general and administrative expenses (to $56.8 million). The company also recorded a $2.4 million impairment of long-lived assets. Net cash used in operating activities was $149.2 million, while net cash provided by investing and financing activities was $95.6 million and $30.2 million, respectively, resulting in a net decrease in cash of $23.5 million. The company ended the period with $93.4 million in cash, cash equivalents, and restricted cash.
The company's revenue is generated from collaboration agreements. For FY 2025, collaboration revenue was $0, compared to $22,000 in FY 2024, which was primarily related to participation in a joint steering committee performance obligation under the License Agreement with Overland Therapeutics. The company has no product sales and anticipates that future revenue may come from product sales, marketing and distribution arrangements, and other collaborations or licensing arrangements, contingent upon successful development and regulatory approval of its product candidates.
As a clinical-stage company with no product revenue, Allogene operates at a loss. The net loss margin improved year-over-year due to reduced operating expenses. Research and development expenses, the largest cost component, decreased by 22% to $150.2 million, driven by lower development costs, personnel expenses, and facilities costs. General and administrative expenses decreased by 13% to $56.8 million, primarily due to reduced personnel costs. The company's cost structure reflects its focus on advancing clinical programs while managing expenditures.
Net cash used in operating activities was $149.2 million for FY 2025, an improvement from $200.3 million used in the prior year, primarily due to a lower net loss and changes in working capital. Cash flows from investing activities provided $95.6 million, mainly from proceeds from maturities of investments of $234.2 million, partially offset by purchases of investments of $138.3 million. Financing activities provided $30.2 million, primarily from net proceeds from ATM offerings ($22.4 million) and proceeds from a CIRM award ($6.9 million). The company's cash, cash equivalents, and restricted cash decreased by $23.5 million to $93.4 million. Total assets were $415.9 million, and total liabilities were $123.4 million as of December 31, 2025.
The company's clinical development priorities are focused on three core programs: the ALPHA3 trial for cema-cel in first-line consolidation for large B-cell lymphoma, the RESOLUTION trial for ALLO-329 in autoimmune diseases, and the TRAVERSE trial for ALLO-316 in renal cell carcinoma. Key near-term milestones include MRD clearance data from the ALPHA3 interim futility analysis expected in April 2026 and initial proof-of-concept data for ALLO-329 expected in June 2026. The company believes its current cash, cash equivalents, and investments of $258.3 million will be sufficient to fund operations into the first quarter of 2028. Management expects to continue to incur net losses for the foreseeable future as research and development expenses increase. The company is exploring strategic opportunities, including potential partnerships, to advance its programs.